DELTA-P --- The stock is at a high buy indication, with approval for tolerability in clinical trials targeted at acute myeloid leukemia, confirming complete remission.

Fisco Japan · Dec 11 11:36

There is a buy signal at the upper limit. Regarding the clinical phase 1/2 trial of "DFP-10917," developed in the USA for patients with acute myeloid leukemia who became ineffective or relapsed after previous treatment (first-line therapy), it was announced after the close of trading on the 9th that the tolerability of the first three cases was approved by the Data Monitoring Committee (DMC), and it continues to be seen as a buying opportunity. The number of bone marrow cells in the peripheral blood became zero within four weeks of starting treatment for all three cases, and complete remission was confirmed in subsequent bone marrow examinations.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

ＤＥＬＴＡ－Ｐ---ストップ高買い気配、急性骨髄性白血病対象の臨床試験で忍容性承認、完全寛解を確認

DELTA-P --- The stock is at a high buy indication, with approval for tolerability in clinical trials targeted at acute myeloid leukemia, confirming complete remission.

Risk Disclaimer

Statement